Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cytograft's New Lifeline for Vascular Surgery

This article was originally published in Start Up

Executive Summary

The creation of durable vascular grafts has been a tantalizing objective for multitudes of companies and research efforts that have applied all the disciplines of medical science to it: tissue engineering, cell-therapies, biomaterials, drugs, and combinations of all of those technologies, but without much success. The complexities of creating a functional structure with biological properties has foiled many a research effort. But now Cytograft Tissue Engineering has a new take on tissue engineering. Cytograft produces a living conduit with the handling properties of a native vessel, built exclusively from the patient's own cells. Unlike previous approaches, Cytograft's Lifeline vascular graft does not require synthetic materials or exogenous scaffolds.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel